top of page

Tokenized Par‑Value Arbitrage

Tokenized Par‑Value Arbitrage™ (TPVA™)

A Global Financial Architecture for Solving the Under‑Par Value Dilemma in Modern Funding Rounds


Short Definition

Tokenized Par‑Value Arbitrage™ (TPVA™) is a globally applicable financial architecture model that resolves under‑par value restrictions, down‑round conflicts, capital maintenance rules, and accounting volatility across different legal systems. TPVA™ separates capital inflows from the legal share structure by using a tokenized convertible bond. This allows companies to raise capital at any price while still meeting the full nominal value at conversion — enabling legally compliant, audit‑stable and governance‑friendly financing in crisis and growth phases.

The Global Funding Problem

Modern companies — especially in Deep Tech, Clean Tech, Robotics, AI, Biotech and Infrastructure — increasingly face situations where:

  • valuations drop sharply (down‑rounds)

  • capital is urgently needed

  • traditional instruments are blocked by legal constraints

  • nominal value rules or capital maintenance regimes apply

  • accounting volatility threatens the P&L

  • governance and cap tables must remain stable


The universal conflict

How can an investor enter at a very low price without violating corporate law, accounting rules or governance structures?



The Three English‑Speaking Capital Systems

The English‑speaking world consists of three fundamentally different capital regimes that treat down‑rounds in very different ways.


United States — Market Logic & Micro‑Par Value

  • Micro Par Value (e.g., $0.00001)

  • No‑Par Shares widely used

  • APIC absorbs valuation differences

  • Down‑rounds are routine

  • SAFE and Convertible Notes dominate early‑stage funding

  • Venture cycles are fast

Key issue

Variable conversion ratios trigger ASC 815 derivative accounting, causing massive P&L volatility.


United Kingdom — Capital Maintenance & Nominal Value

  • Nominal Value is legally binding

  • Under‑par issuance strictly prohibited

  • Companies Act 2006 enforces capital maintenance

  • FCA rules add governance and disclosure requirements

  • IFRS is the accounting standard

  • Register processes are formal and slow

Key issue

Down‑rounds cannot be executed below nominal value without a capital reduction — slow, expensive, reputationally damaging.


Commonwealth Economies — IFRS Hybrid Systems

(Canada, Australia, New Zealand, Singapore, Hong Kong)

  • IFRS accounting

  • Nominal value often exists

  • Under‑par issuance usually prohibited

  • Some jurisdictions allow No‑Par Shares (Singapore, Hong Kong)

  • Tokenization increasingly regulated and accepted

Key issue

Down‑rounds require complex capital measures or hybrid instruments — often too slow for fast‑moving markets.



Why Classical Solutions Fail (USA + UK + Commonwealth)

Capital Reduction (UK, Commonwealth)

Slow, expensive, requires shareholder approval, often damages market perception.

Convertible Notes / SAFE (USA)

Effective in the U.S., but:

  • often not legally compatible in UK/EU

  • often not IFRS‑compliant

  • often trigger derivative accounting under ASC 815

Traditional Convertible Bonds

Shift the under‑par problem to the conversion moment — not a real solution.

Preferred Rights / Liquidation Preferences

Complex, governance‑heavy, often disliked by auditors.

Direct Equity Issuance

Blocked by nominal value rules in UK/Commonwealth. Blocked by capital maintenance rules in EU. Blocked by ASC 815 in the U.S. if ratios are variable.



The Solution: Tokenized Par‑Value Arbitrage™ (TPVA™)

TPVA™ is a global financial architecture that enables down‑rounds without violating capital maintenance rules or triggering derivative accounting.

Step 1 — Investor buys tokens, not shares

  • Tokenized Convertible Bond

  • Classified as debt or mezzanine

  • No nominal value on token level

  • No under‑par conflict

Step 2 — Smart Contract defines the conversion ratio

Example: 10 tokens at $0.01 convert into 1 share with $0.10 nominal value.

This creates:

  • Ratio Shield

  • Fixed‑for‑Fixed compliance under IFRS

  • ASC 815 avoidance under US‑GAAP

Step 3 — Full nominal value at conversion

  • tokens extinguished

  • company receives full nominal value

  • capital maintenance rules fully respected

Step 4 — Pre‑IPO liquidity via regulated token markets

  • tokens tradable

  • investor gains early liquidity

  • cap table remains clean

  • founders retain control



Global Accounting Logic (US‑GAAP + IFRS)

IFRS (IAS 32 / IFRS 15)

  • Fixed‑for‑Fixed classification possible

  • clean equity/debt split

  • no recurring fair‑value P&L volatility

  • ideal for UK, Commonwealth, EU, Asia


US‑GAAP (ASC 480 / ASC 815)

  • Micro‑Par Value solves under‑par

  • variable ratios trigger derivative accounting

  • TPVA™ avoids this by fixing the conversion ratio


UK / Commonwealth Corporate Law

  • nominal value fully respected

  • capital maintenance rules satisfied

  • register entries only at conversion



Global Comparison Matrix (English‑Speaking Focus)

Region

Nominal Value System

Under‑Par Rules

Accounting

Down‑Round Problem

Token Compatibility

Notes

USA

Micro Par / No‑Par

irrelevant

US‑GAAP

ASC 815 volatility

high

VC‑driven, fast cycles

UK

Nominal Value

prohibited

IFRS

capital reduction required

high

Companies Act 2006

Canada

mixed

varies

IFRS / ASPE

hybrid issues

high

flexible corporate law

Australia

nominal

prohibited

IFRS

strict capital maintenance

high

ASIC rules

New Zealand

nominal

prohibited

IFRS

conservative

high

Companies Act NZ

Singapore

No‑Par

allowed

IFRS

flexible

very high

MAS token‑friendly

Hong Kong

No‑Par

allowed

IFRS

market‑driven

very high

SFC token‑friendly



Why TPVA™ Works Across All English‑Speaking Jurisdictions

  • respects nominal value (UK, Commonwealth)

  • avoids under‑par issuance

  • avoids ASC 815 derivative accounting (USA)

  • avoids capital reduction processes

  • avoids governance dilution

  • avoids register delays

  • enables early liquidity

  • supports Pre‑IPO funding

  • works under IFRS and US‑GAAP

  • culturally neutral

  • regulatorily adaptable


TPVA™ is the first model that works across:

  • USA

  • UK

  • Canada

  • Australia

  • New Zealand

  • Singapore

  • Hong Kong

simultaneously.



Regional Examples (USA + UK + Commonwealth)

Silicon Valley (USA)

A robotics scale‑up faces a 90% valuation drop. A direct equity round triggers ASC 815 derivative accounting. TPVA™ allows a low entry price without P&L volatility.

London (UK)

A fintech cannot issue shares below nominal value. Capital reduction would take months. TPVA™ enables immediate funding while respecting nominal value.

Singapore (Commonwealth)

A climate‑tech company wants Pre‑IPO liquidity. Tokens can be traded on MAS‑regulated DLT markets. TPVA™ keeps the cap table clean.

Toronto (Canada)

A biotech firm must comply with IFRS and provincial corporate law. TPVA™ avoids under‑par conflicts and derivative accounting.

Sydney (Australia)

A deep‑tech scale‑up faces strict capital maintenance rules. TPVA™ satisfies ASIC requirements while enabling down‑round pricing.




Regional Extensions and Global Application

The core mechanism of Tokenized Par‑Value Arbitrage™ (TPVA™) is globally applicable. However, capital‑market rules, accounting standards and financing practices differ significantly across jurisdictions. To reflect these differences, TPVA™ is presented in four regional language versions. Each version expands the global core with the regulatory, cultural and economic characteristics of its respective financial system:






NextLevel Statement

Tokenized Par‑Value Arbitrage™ (TPVA™) demonstrates that modern financial architecture is not about bypassing legal or accounting regimes, but about designing systems that behave consistently across jurisdictions, cultures and market logics. TPVA™ reframes down‑rounds from a legal impossibility into an architectural design challenge: capital inflows, nominal value logic and accounting treatment are decoupled, re‑orchestrated and transformed into a universal, cross‑jurisdictional financing model. For the first time, companies can execute legally compliant, audit‑stable and governance‑friendly funding rounds that work equally well in the United States, the United Kingdom, Canada, Australia, Singapore and Hong Kong — keeping high‑growth companies operational in critical phases.






FAQs — Funding Challenges in the English‑Speaking World

How can I raise capital if an investor demands a price far below my nominal value?

Use an instrument with no nominal value, delivering full nominal value only at conversion.

How can I execute a down‑round without violating UK nominal value rules?

Separate entry price from share structure — conversion must deliver full nominal value.

How can I avoid ASC 815 derivative accounting in the U.S.?

Use a fixed conversion ratio to prevent fair‑value remeasurement.

How can I raise capital without triggering a capital reduction in the UK?

Use a structure that does not issue shares until nominal value is met.

How can I raise capital without immediate dilution?

Use an instrument that creates no voting rights until conversion.

How can I avoid damaging my cap table during a crisis round?

Raise capital through a non‑equity instrument that converts later.

How can I avoid triggering covenants during a down‑round?

Use a structure that does not reduce equity at funding time.

How can I raise capital if my company is incorporated in multiple jurisdictions?

Use a jurisdiction‑neutral instrument that converts locally.

How can I avoid reputational damage from a down‑round?

Ensure the low entry price applies to a separate instrument, not the share price.

How can I raise capital without triggering UK Companies Act restrictions?

Use a structure that respects nominal value at conversion.

How can I raise capital without triggering US‑GAAP fair‑value volatility?

Avoid variable conversion ratios.

How can I raise capital without triggering IFRS equity reclassification?

Use a Fixed‑for‑Fixed compliant structure.

How can I raise capital without requiring shareholder approval for a capital reduction?

Avoid any change to nominal value.

How can I raise capital without slowing down due to register processes?

Use an instrument requiring register entry only at conversion.

How can I raise capital without damaging ESOP programs?

Avoid immediate dilution.

How can I raise capital without triggering regulatory filings?

Use a structure that is not a security until conversion.

How can I raise capital without triggering UK pre‑emption rights?

Use a non‑equity instrument.

How can I raise capital without triggering Canadian provincial restrictions?

Use a structure that converts under local rules.

How can I raise capital without triggering Australian capital maintenance rules?

Ensure full nominal value is met at conversion.

How can I raise capital without triggering Singapore MAS prospectus rules?

Use a tokenized instrument classified as debt.

How can I raise capital without triggering Hong Kong SFC equity rules?

Use a non‑equity instrument.

How can I raise capital without triggering U.S. investor control?

Avoid immediate voting rights.

How can I raise capital without triggering UK dilution concerns?

Delay conversion.

How can I raise capital without triggering IFRS fair‑value volatility?

Use fixed ratios.

How can I raise capital without triggering US‑GAAP embedded derivative rules?

Avoid variable conversion mechanics.

How can I raise capital without triggering governance instability?

Use non‑voting instruments.

How can I raise capital without triggering cross‑border legal conflicts?

Use a globally compatible architecture.

How can I raise capital without triggering negative market perception?

Separate entry price from share price.

How can I raise capital without triggering audit objections?

Use a structure that is clean under IFRS and US‑GAAP.

How can I raise capital without triggering shareholder disputes?

Avoid immediate equity issuance.

How can I raise capital without triggering valuation write‑downs?

Ensure the low entry price applies to a separate instrument.

How can I raise capital without triggering regulatory delays?

Use a structure that converts later.

How can I raise capital without triggering long approval cycles?

Avoid capital reductions.

How can I raise capital without compromising long‑term strategy?

Use a structure that preserves governance and flexibility.

bottom of page